Pilot trial suggests structured support may help limit weight regain after GLP-1 treatment

Glucagon-like peptide-1 (GLP-1) receptor agonists are effectual treatments for obesity, but discontinuation is communal owed to cost, security sum limitations, broadside effects, diligent penchant and different factors—and often leads to accelerated value regain. Results from a aviator randomized trial, published successful Obesity Science & Practice, suggest that structured enactment whitethorn attenuate aboriginal value summation aft GLP-1 cessation.